Artificial intelligence (AI) has been widely used to discover new drugs, but Singapore-based ChemT Biotechnology is betting the technology can also help solve one of the pharmaceutical industry’s biggest challenges: manufacturing them at scale.
The startup said it had secured $4 million in its Seed funding round, anchored by Wavemaker Ventures and SEEDS, to expand its AI-driven platform.
The platform aims to improve biologics manufacturing, a process that ChemT said often hampered by long development timelines, unpredictable yields, and high production costs.
The round brings ChemT’s total funding to $5 million within 18 months, including $1 million in angel investment. Other investors in the seed round include Wavemaker 360 Health, Draper University Ventures, and Temasek Life Sciences Accelerator, per the announcement.
Read Full Article At Source
